Fidelity Advisor Biotechnology Fund - Class C (FBTCX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
28.86
-0.07 (-0.24%)
At close: Feb 13, 2026
Fund Assets1.87B
Expense Ratio1.76%
Min. Investment$0.00
Turnover51.00%
Dividend (ttm)0.48
Dividend Yield1.67%
Dividend Growth-66.48%
Payout Frequencyn/a
Ex-Dividend DateDec 26, 2025
Previous Close28.93
YTD Return0.52%
1-Year Return41.08%
5-Year Return31.74%
52-Week Low16.77
52-Week High30.14
Beta (5Y)n/a
Holdings88
Inception DateDec 27, 2000

About FBTCX

Fidelity Advisor Biotechnology Fund Class C is a mutual fund that primarily invests in companies within the biotechnology sector. Its central objective is capital appreciation, achieved by allocating at least 80% of its assets to securities of firms engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. The fund is notably concentrated in the healthcare industry, focusing on businesses that benefit significantly from advances in biotechnology, such as pharmaceuticals and innovative therapeutic providers. The portfolio often holds a high percentage of assets in its top holdings, which typically include leading biotechnology and pharmaceutical companies. With total assets exceeding $1.3 billion, the fund plays a prominent role in offering investors exposure to the dynamic and innovation-driven field of biotechnology. The fund’s investment style is characterized as “mid-blend,” and it is managed with an emphasis on capturing the growth potential within the sector while balancing risk through diversified holdings of both large and emerging biotech firms. This fund is part of Fidelity’s suite of sector-specific offerings, serving investors seeking targeted access to the biotechnology market.

Fund Family Fidelity
Category Health
Performance Rating Average
Risk Rating Above Average
Stock Exchange NASDAQ
Ticker Symbol FBTCX
Share Class Class C
Index S&P 500 TR

Performance

FBTCX had a total return of 41.08% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.13%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

SymbolShare ClassExpense Ratio
FIJYXClass Z0.61%
FBTIXClass I0.74%
FBTAXClass A1.01%
FBTTXClass M1.29%

Top 10 Holdings

53.99% of assets
NameSymbolWeight
AbbVie Inc.ABBV17.22%
Alnylam Pharmaceuticals, Inc.ALNY6.31%
Gilead Sciences, Inc.GILD5.75%
argenx SEARGX4.55%
Ascendis Pharma A/SASND4.29%
Cogent Biosciences, Inc.COGT3.98%
Insmed IncorporatedINSM3.40%
Viridian Therapeutics, Inc.VRDN3.01%
Biogen Inc.BIIB2.81%
Amgen Inc.AMGN2.68%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 26, 2025$0.483Dec 29, 2025
Dec 26, 2024$1.441Dec 27, 2024
Dec 17, 2021$5.241Dec 20, 2021
Jul 9, 2021$0.006Jul 12, 2021
Dec 18, 2020$2.732Dec 21, 2020
Dec 20, 2019$1.849Dec 23, 2019
Full Dividend History